Concomitant RA medications were permitted at the discretion of the investigator and included: methotrexate, leflunomide, sulfasalazine, antimalarials, auranofin
injectable gold preparations, nonsteroidal anti-inflammatory drugs, and/or glucocorticoids at approved doses.
exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis.
(168) Nora Yang, Auranofin
for Chronic Lymphocytic Leukemia,
Klegeris, "A new look at auranofin
, dextromethorphan and rosiglitazone for reduction of glia-mediated inflammation in neurodegenerative diseases," Neural Regeneration Research, vol.
suppresses plasminogen activator inhibitor-2 expression through annexin A5 induction in human prostate cancer cells," Biomolecules & Therapeutics, vol.
crassiceps TGR was obtained by incubating an enzyme aliquot in the presence of a 4:1 molar excess of the irreversible inhibitor auranofin
A number of new molecules have been identified as inhibitors of IL-1[beta] processing (glyburide, parthenolide, CRID3, auranofin
, isoliquiritigenin, [beta]-hydroxybutyrate, and MCC950); however, confirming their clinical utility will require additional time and research .
, a gold-containing chemical applied for treatment of rheumatoid arthritis, inhibits thioredoxin reductase, inducing ROS formation and in this way dramatically inhibiting GIST cell growth, and it also induces apoptosis in imatinib-resistant cells .
Module Drug Drug Drug class target (2) JAK1 Tofacitinib DMARDs JAK2 Tofacitinib DMARDs (4) IL1B Canakinumab Biotech agents IL6R Tocilizumab Biotech agents LTA Etanercept Biotech agents Etanercept Biotech agents Adalimumab Biotech agents TNF Infliximab Biotech agents Golimumab Biotech agents Certolizumab pegol Biotech agents Chloroquine DMARDs TNFRSF1B Etanercept Biotech agents (5) IL1R1 Anakinra Biotech agents (6) PTK2B Leflunomide DMARDs (7) MAPK3 Sulindac NSAIAs CHUK Sulfasalazine DMARDs (8) IKBKB Sulfasalazine DMARDs Auranofin
DMARDs (9) PDPK1 Celecoxib NSAIAs (10) BCL2 Ibuprofen NSAIAs
cDMARDs n (%) Patients with at 11,511 (91.9%) least one treatment Methotrexate 9,508 (75.9%) Hydroxychloro quine 3,527 (28.2%) Leflunomide 3,275 (26.1%) Sulfasalazine 2,340 (18.7%) Sodium aurothiomalate 114 (0.9%) Azathioprine 98 (0.8%) Cyclosporine 89 (0.7%) Auranofin
43 (0.3%) Penicillamine 28 (0.2%) Cyclophosphamide 10 (0.1%) bDMARDs n (%) Patients with at 3,697 (29.5%) least one treatment Etanercept 1,545 (12.3%) Adalimumab 1,329 (10.6%) Tocilizumab 618 (4.9%) Abatacept 481 (3.8%) Golimumab 376 (3.0%) Rituximab 339 (2.7%) Certolizumab pegol 273 (2.2%) Infliximab 68 (0.5%) Anakinra 3 (<1.0%) Table 3: Change in DAS28-ESR scores over a 6-month period.
blocks interleukin-6 signalling by inhibiting phosphorylation of JAK1 and STAT3.
displays anticancer activity against ovarian cancer cells through FOXO3 activation independent of p53.